Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.27
+1.55 (2.55%)
At close: Mar 4, 2026, 4:00 PM EST
62.27
0.00 (0.00%)
After-hours: Mar 4, 2026, 4:02 PM EST
Cytokinetics Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 86, with a low estimate of 41 and a high estimate of 136. The average target predicts an increase of 38.11% from the current stock price of 62.27.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock from 18 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 7 | 7 |
| Buy | 9 | 8 | 8 | 8 | 9 | 9 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 15 | 16 | 16 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $83 → $84 | Buy | Maintains | $83 → $84 | +34.90% | Feb 26, 2026 |
| Citizens | Citizens | Buy Maintains $88 → $96 | Buy | Maintains | $88 → $96 | +54.17% | Feb 25, 2026 |
| Needham | Needham | Strong Buy Maintains $84 → $85 | Strong Buy | Maintains | $84 → $85 | +36.50% | Feb 25, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $95 → $101 | Buy | Maintains | $95 → $101 | +62.20% | Feb 20, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $84 → $92 | Strong Buy | Maintains | $84 → $92 | +47.74% | Feb 3, 2026 |
Financial Forecast
Revenue This Year
96.66M
from 88.04M
Increased by 9.79%
Revenue Next Year
389.20M
from 96.66M
Increased by 302.66%
EPS This Year
-6.69
from -6.54
EPS Next Year
-4.83
from -6.69
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 132.3M | 669.6M | |||
| Avg | 96.7M | 389.2M | |||
| Low | 61.7M | 289.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 50.3% | 592.8% | |||
| Avg | 9.8% | 302.7% | |||
| Low | -29.9% | 199.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -5.96 | -2.93 | |||
| Avg | -6.69 | -4.83 | |||
| Low | -7.09 | -5.72 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.